{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["44(2)"],"submitter":["Radcliffe C"],"pubmed_abstract":["Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic."],"journal":["Clinics in chest medicine"],"pagination":["279-297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9701636"],"repository":["biostudies-literature"],"pubmed_title":["Antiviral Treatment of Coronavirus Disease-2019 Pneumonia."],"pmcid":["PMC9701636"],"pubmed_authors":["Malinis M","Radcliffe C","Azar MM"],"additional_accession":[]},"is_claimable":false,"name":"Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.","description":"Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-19T22:46:46.046Z","creation":"2025-04-19T22:46:46.046Z"},"accession":"S-EPMC9701636","cross_references":{"pubmed":["37085220"],"doi":["10.1016/j.ccm.2022.11.008"]}}